Key Highlights

  • Novartis (NYSE:NVS) reports before the Swiss market open on Tuesday, October 27, 2026, against consensus earnings of USD 2.24 per American depositary share, below second-quarter core earnings of USD 2.41, with 2026 guidance reaffirmed.
  • Kiniksa Pharmaceuticals (NASDAQ:KNSA) reports before the open against consensus of USD 0.31 per share, after raising 2026 Arcalyst revenue guidance to USD 980 million to USD 995 million and holding USD 525.9 million of cash.
  • Summit Therapeutics (NASDAQ:SMMT) reports after the close against a consensus loss of USD 0.21 per share, with a Food and Drug Administration decision on ivonescimab cited for Saturday, November 14, 2026.
  • Wave Life Sciences (NASDAQ:WVE) reports before the open against a consensus loss of USD 0.32 per share, with cash of USD 490.6 million said to fund operations into the third quarter of 2028.

Novartis (NYSE:NVS): growth brands against generic erosion

Novartis (NYSE:NVS), the Swiss pharmaceutical group focused on innovative medicines, reports third-quarter results on Tuesday, October 27, 2026, ahead of the Swiss market open. Consensus earnings are USD 2.24 per American depositary share, which may be on a different basis from core earnings. The second-quarter report of Tuesday, July 21, 2026 showed net sales of USD 14.4 billion, up 1% in constant currencies, core operating income of USD 5.9 billion and core earnings of USD 2.41 per share. Guidance was reaffirmed: low single-digit sales growth and a low single-digit decline in core operating income. Results cannot be known in advance.

Novartis is judged on whether new medicines grow faster than older ones lose sales to generics. In the second quarter Kisqali grew 43% and Kesimpta 32% in constant currencies, while Entresto fell about 51%. Barclays has cut its target on the shares to CHF 125 and the consensus among analysts is described as Hold. The bull case is a core margin holding near 41.2%, growth above the guided pace and a raised outlook, which could prompt a relief move. The bear case is slower growth for Kisqali, faster Entresto erosion or a United States pricing action. A strong Swiss franc also reduces the value of dollar and euro sales when reported in dollars.

Kiniksa Pharmaceuticals (NASDAQ:KNSA): one launched product and a second in Phase 3

Kiniksa Pharmaceuticals (NASDAQ:KNSA) sells Arcalyst, a treatment for recurrent pericarditis, which is repeated inflammation of the sac around the heart, and it reports before the open on Tuesday, October 27, 2026. Consensus earnings are USD 0.31 per share. In the second quarter, total revenue of USD 243.6 million compared with USD 156.8 million a year earlier, and diluted earnings were USD 0.30 against USD 0.23. The guidance raise of USD 50 million at both ends of the range left a new full-year Arcalyst range of USD 980 million to USD 995 million. Cash and short-term investments were USD 525.9 million with no debt.

With a single marketed product, patients treated, length of therapy and net price after rebates drive nearly all results. KPL-387, an antibody aimed at the same pathway, is in the pivotal PASTORALE study, with launch targeted for 2028 or 2029. The bull case is sales tracking toward the top of the range and a further guidance lift, which would extend a rerating that saw the shares rise about 21% after the second-quarter report. The bear case is a sequential slowdown in prescriptions, higher spending or a range left unchanged. Competitive therapies and payer pressure on pricing are further risks.

Summit Therapeutics (NASDAQ:SMMT): a regulatory decision after the quarter

Summit Therapeutics (NASDAQ:SMMT) develops ivonescimab, a bispecific antibody that blocks both PD-1, a protein that restrains immune attack on tumours, and VEGF, a driver of tumour blood supply. It reports third-quarter results after the close on Tuesday, October 27, 2026, with consensus at a loss of USD 0.21 per share. The company has no marketed product, so the loss tracks research spending, trial costs and pre-launch hiring. The United States Food and Drug Administration accepted the biologics licence application, and published reports cite a decision date of Saturday, November 14, 2026.

The application rests on the Phase III HARMONi study in patients with EGFR-mutant non-small cell lung cancer whose disease progressed after a targeted therapy. The earlier readout did not show a statistically significant benefit on overall survival, which keeps the review a focus. The bull case is a loss at or below USD 0.21, a cash position that covers the launch and confirmation that the review is on schedule. The bear case is a wider loss, financing that dilutes holders or any hint of a delay, which could cut the shares sharply because the valuation depends on one product.

Wave Life Sciences (NASDAQ:WVE): milestones against a long runway

Wave Life Sciences (NASDAQ:WVE) develops RNA medicines, which are drugs that edit or silence genetic messages, and it is expected to report before the open on Tuesday, October 27, 2026. Consensus calls for a loss of USD 0.32 per share. In the second quarter, reported on Thursday, July 30, 2026, the net loss was USD 69.4 million, or USD 0.34 per share, and revenue fell to USD 2.3 million from USD 8.7 million. Cash, equivalents and marketable securities were USD 490.6 million at June 30, 2026, down from USD 602.1 million at the end of 2025.

For a clinical-stage company the quarterly loss is largely predictable, and the bar is set by pipeline timing. Management expected single-dose data for the obesity candidate WVE-007 in the second half of 2026, and a regulator meeting on an accelerated route for WVE-006, an alpha-1 antitrypsin deficiency candidate. The bull case is a firm data date, a clear regulatory outcome or a partnership for a mid-stage asset. The bear case is a slip in timing or a wider loss, which would raise financing worries even with the cash on hand.

Where Things Stand

The answer is that the group splits between companies funded by revenue and companies funded by cash. Novartis (NYSE:NVS) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) fund pipelines from launched products, so brand growth and the USD 980 million to USD 995 million Arcalyst range are the tests. Summit Therapeutics (NASDAQ:SMMT) and Wave Life Sciences (NASDAQ:WVE) depend on cash balances and milestones, so the dated decision on Saturday, November 14, 2026 and the second-half data readouts matter more than their per share losses. Higher rates raise the cost of raising capital for the cash-funded pair.

The next catalysts are the Novartis, Kiniksa and Wave releases before the open and the Summit release after the close on Tuesday, October 27, 2026, followed by the Federal Reserve decision on Wednesday, October 28, 2026. Forecasts, timetables and decision dates can change, clinical results are uncertain, and this is not investment advice.